Blinatumomab compared with standard of care for the treatment of adult patients with relapsed/refractory Philadelphia chromosome-positive B-precursor acute lymphoblastic leukemia.
Alessandro RambaldiJosep-María RiberaHagop M KantarjianHervé DombretOliver G OttmannAnthony S SteinCatherine A TuglusXiaoyue ZhaoChristopher KimGiovanni MartinelliPublished in: Cancer (2019)
These results further support blinatumomab as a treatment option for patients with r/r Ph+ ALL.